Key statistics dashboard for BeyondSpring Inc. (BYSI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.
Stock Data
| Price | $0.71 |
| Market Cap | $29M |
| Beta | 0.51 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -4.29 |
| Price / Book | -0.82 |
| P/S | 0.00 |
| P/FCF | -1.71 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 0.70 |
| Quick Ratio | 0.70 |
| Cash Ratio | 0.19 |
| Debt / Equity | -0.00 |
| Debt / Assets | 1.17% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | -0.88 |
| Cash per share | 0.16 |
| FCF per share | -0.41 |
| Tangible Book Value per share | -0.88 |
| Dividend per share | 0.00 |
Related companies: ALXO · ATYR · BMEA · CAMP · DTIL · GUTS · HYFT
Explore sector: Healthcare · Biotechnology
More sections of BYSI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks